BMS partners with Repertoire and Scenic, plus deals involving: G1/Pepper, Harmony/Epygenix, Biodexa/Emtora, Regeneron/Mammoth, Vertex/Treefrog and Immedica/KKR/Impilo.

After reducing 500 employees last year while reorganizing its subsidiaries in the US in the aftermath of patent expiration for its mainstay product Latuda, the Japanese firm has decided to move ahead with another rationalization affecting 400 employees there.

Global crises and a tough funding environment mean biopharma leadership teams need to work hard to survive, let alone thrive. Industry executives shared their predictions and advice on strategy for 2024.

Getting on the best reimbursement pathway in the US will be vital for the UK company as it moves closer to approval and taking on the established players in the chronic obstructive pulmonary disease arena.